Wellcome Sanger Institute
Cambridge, United Kingdom
NCT Number: NCT06832150
Recently technology has been developed at the Wellcome Sanger Institute to allow clusters of cells with mutations to be detected in normal and diseased tissues. The researchers wish to determine how the number and nature of these mutant cell clusters change in response to treatments given to cancer patients (such as chemotherapy, radiotherapy, immunotherapy, and drugs targeted at specific mutations in tumours). As such the researchers wish to collect research samples of blood, cheek cells (via swabs) and urine from adult cancer patients receiving the above-mentioned treatments as part of their standard care. The researchers also wish to access any leftover tissue following surgery that is undertaken as part of these patient's treatment.
Interested in participating?
Request Info18 year–99 year
All sexes
Observational
Cambridge, United Kingdom
Disease and tissue aging are thought to be influenced by genetic changes, or mutations, acquired throughout life. These mutations provide clues regarding the genetic damage that occurred through the lifetime of the patient, and include mutations caused by environmental factors such as ultraviolet light from sunlight or tobacco smoke affecting the skin or internal tissues, respectively. Other mutations may occur due to errors in copying the genome as cells divide. Once a cell has acquired a mutation, the cell's daughters may inherit it. Eventually clusters of cells carrying the same mutation may form within tissues. If the mutations alter cell behaviour this may impact how cells behave and influence how a whole tissue functions.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants may collected their own cheek swabs and will collect their own urine samples.
Clinical professionals at participating sites will collect blood samples.
Research Nurse/ Suitably qualified Research Site Staff will discuss the study with potential participants
Potential participants who wish to give consent will do with a Research Nurse/ Suitably qualified Research Site Staff.
Time frame: 5 years
The study will measure the frequency, size and nature of acquired (somatic) mutations in clusters of cells in normal blood, urinary tract and oral cells changes after cancer treatment.
Time frame: 5 years
The study will measure the size of acquired (somatic) mutations in clusters of cells in normal blood, urinary tract and oral cells changes after cancer treatment.
Time frame: 5 years
The study will attempt to define and/or understand the behaviour/ nature of acquired (somatic) mutations in clusters of cells in normal blood, urinary tract and oral cells changes after cancer treatment.
The Wellcome Sanger Institute
Other
Acronym: SMS2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06851052
Somatic Mutation
Cambridge, United Kingdom
View Trial DetailsNCT06917794
Cancer Predisposition Syndrome, Colo-rectal Cancer
Fortaleza, Ceará, Brazil
View Trial DetailsNCT06656767
Chronic Liver Disease, Somatic Mutation
Cambridge, United Kingdom
View Trial DetailsNCT06585800
Somatic Mutation
Cambridge, United Kingdom
View Trial Details